Get the Stockscreener App
0.2033
9.29%
-0.0248
Cosmos Health Inc stock is traded at $0.2033, with a volume of 3.79M.
It is down -9.29% in the last 24 hours and down -32.58% over the past month.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
See More
Previous Close:
$0.2281
Open:
$0.2263
24h Volume:
3.79M
Relative Volume:
2.88
Market Cap:
$12.48M
Revenue:
$69.49M
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.3133
EPS:
-0.649
Net Cash Flow:
$-14.46M
1W Performance:
-23.62%
1M Performance:
-32.58%
6M Performance:
-53.60%
1Y Performance:
-58.04%
1-Day Range:
$0.196
$0.2263
1-Week Range:
$0.1952
$0.2799
52-Week Range:
$0.1952
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2011 | 14.16M | 69.49M | -21.13M | -14.46M | -0.649 |
MCK
Mckesson Corp
|
791.73 | 95.01B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
282.63 | 54.72B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
223.18 | 50.66B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
80.06 | 8.98B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.37 | 1.19B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health Secures Additional 180-Day Nasdaq Extension To Regain Bid Price Compliance - TradingView
Cosmos Health gets Nasdaq extension to regain $1 minimum bid price - Investing.com
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance - lincolnjournal.com
Cosmos Health CEO addresses shareholders amid stock decline - Investing.com UK
Cosmos Health targets $200M revenue by 2029, driven by U.S. expansion - scanx.trade
$20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM) - Barchart.com
Cosmos Health (COSM) Secures Manufacturing Deal with Verisfield S.A. - GuruFocus
Cosmos Health subsidiary secures manufacturing deal - Investing.com
Cosmos Health Inc. - Via Ritzau
Cosmos Health CEO addresses shareholders amid stock decline By Investing.com - Investing.com Canada
Cosmos Health CEO Issues Letter to Shareholders: Building - GlobeNewswire
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway - Yahoo Finance
Cosmos Health subsidiary secures 5-year manufacturing deal - Investing.com UK
Cosmos Health (COSM) Launches New Capsule Production and Signs C - GuruFocus
Cosmos Health subsidiary secures 5-year manufacturing deal By Investing.com - Investing.com Canada
Cosmos Health Inc. Subsidiary Cana Laboratories Inaugurates New Capsule Production Line and Secures Contract with Provident Pharmaceuticals - Quiver Quantitative
Factory upgrade backs 385,000-dose antidepressant deal contract - Stock Titan
Cosmos Health (COSM) Expands Innovation with Patent Acquisition - GuruFocus
Cosmos Health subsidiary acquires nanotechnology patent By Investing.com - Investing.com Australia
Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives - The Manila Times
Cosmos Health subsidiary acquires nanotechnology patent - Investing.com
Cosmos Health Inc. Subsidiary Cana Laboratories Acquires International Patent to Enhance Nanotechnology Investment Initiatives - Quiver Quantitative
Cosmos Health Completes Acquisition of Strategic - GlobeNewswire
New nanotech patent backs Cosmos Health’s next-gen pharma plans - Stock Titan
Andreas Bovopoulos holds 4.32M Cosmos Health (COSM) shares — Schedule 13G/A - Stock Titan
Cosmos Health Inc.: Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories - FinanzNachrichten.de
Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories - The Manila Times
New Oliv18 capsule packs 11 tsp of olive oil for heart support - Stock Titan
Key facts: Cosmos Health may monetize ~$15M assets; lists 96 products EU - TradingView
Cosmos Health Inc. (NASDAQ: COSM) $200M shelf; discloses crypto treasury strategy - Stock Titan
Cosmos Health expands Sky Premium Life to all 27 EU states - Investing.com UK
Cosmos Health launches Fort18 men’s wellness supplement in U.S. - Investing.com
$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM) - Barchart.com
Cosmos Health expands Sky Premium Life to all 27 EU states By Investing.com - Investing.com South Africa
Vitamins brand Sky Premium Life goes on sale in all 27 EU countries - Stock Titan
Cosmos Health (COSM) to Explore Monetization of Non-Core Assets - GuruFocus
Cosmos Health explores sale of non-core assets worth $20M By Investing.com - Investing.com India
Cosmos Health explores sale of non-core assets worth $20M - Investing.com Nigeria
Cosmos Health Identifies Approximately $20 Million in - GlobeNewswire
Cosmos Health Inc. Identifies $20 Million in Non-Core Assets for Potential Monetization - Moomoo
Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value - The Globe and Mail
Cosmos Health Bets the Farm—Literally—on a $20 Million Revival Plan - BriefGlance
Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029 - WBOC TV
Cosmos Health (NASDAQ: COSM) outlines 2026 proxy, 10M-share equity plan and Series B preferred - Stock Titan
Cosmos Health reports balance sheet improvements, EIB talks By Investing.com - Investing.com South Africa
Cosmos Health reports balance sheet improvements, EIB talks - Investing.com
Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent S - The Manila Times
Cosmos Health trims $4.5M debt, weighs €25M EIB deal, drops 38% warrants - Stock Titan
Cosmos Health Provides Balance Sheet Update: Highlights - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cosmos Health extends C-Scrub brand into veterinary market By Investing.com - Investing.com South Africa
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cosmos Health Inc Stock (COSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
| Siokas Grigorios | Chief Executive Officer |
Jan 08 '26 |
Buy |
0.52 |
156,190 |
81,000 |
7,131,794 |
| Siokas Grigorios | Chief Executive Officer |
Jan 07 '26 |
Buy |
0.52 |
124,880 |
65,000 |
6,975,604 |
| Siokas Grigorios | Chief Executive Officer |
Jan 06 '26 |
Buy |
0.54 |
133,953 |
72,000 |
6,850,724 |
| Siokas Grigorios | Chief Executive Officer |
Dec 19 '25 |
Buy |
0.49 |
88,314 |
43,000 |
6,716,771 |
| Siokas Grigorios | Chief Executive Officer |
Dec 15 '25 |
Buy |
0.42 |
168,472 |
70,000 |
6,628,457 |
14.34%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):